Payment overview · 2025
General Payments
$1,483.15
67 reported records · 21 companies
Healthcare provider profile · identity verified
Drew S. Dill, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · MEMPHIS, TN · NPI 1578723276
Verified facts
What the public records show
CMS Open Payments records show Drew S. Dill, MD received $1,483.15 in general payments during 2025 across 67 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Imbruvica, Ninlaro, Verzenio, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Imbruvica by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tagrisso by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Pomalyst by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Sprycel by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Verzenio by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xtandi by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NINLARO as an associated drug or biological on 3835 records involving 2551 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ninlaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.42 | 13.7% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $173.70 | 11.7% | 12 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $129.77 | 8.8% | 5 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $128.82 | 8.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $119.57 | 8.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $114.81 | 7.7% | 5 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $97.39 | 6.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.73 | 4.6% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $65.99 | 4.5% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.11 | 4.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $49.73 | 3.4% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $43.21 | 2.9% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $43.21 | 2.9% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $34.56 | 2.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.25 | 2.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.62 | 1.5% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $21.25 | 1.4% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.75 | 1.3% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.34 | 1.3% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $19.31 | 1.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.61 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,408.15 | 66 |
| Education | $75.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $230.24 | 11 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $128.82 | 5 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $97.39 | 4 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $80.93 | 7 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $79.50 | 3 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $79.50 | 3 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $76.12 | 4 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $65.99 | 2 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $60.11 | 2 | 2025 |
Source payment records
|
|||||
| BENEFIX Normalized: benefix |
Biological | PFIZER INC. | $49.88 | 2 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $49.88 | 2 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $49.73 | 2 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $45.45 | 2 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $45.45 | 2 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $45.45 | 2 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $43.21 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Padcev Normalized: padcev |
Drug | Astellas Pharma US Inc | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NINLARO ninlaro |
2025 | Ninlaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 45 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 45 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | NINLARO open payments reported associated product |
CMS Open Payments — General Payments 3835 supporting records · 2551 recipient NPIs · example record 1223616278 |
Ninlaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Letrozole | Letrozole | 380 | 93 |
| Eliquis | Apixaban | 202 | 45 |
| Ondansetron Odt | Ondansetron | 114 | 56 |
| Tamoxifen Citrate | Tamoxifen Citrate | 88 | 32 |
| Dexamethasone | Dexamethasone | 86 | 36 |
| Xarelto | Rivaroxaban | 75 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 20 |
| Verzenio | Abemaciclib | 56 | suppressed |
| Acyclovir | Acyclovir | 51 | 16 |
| Hydroxyurea | Hydroxyurea | 50 | 15 |
| Anastrozole | Anastrozole | 43 | 15 |
| Gabapentin | Gabapentin | 42 | 16 |
| Lenalidomide | Lenalidomide | 42 | suppressed |
| Revlimid | Lenalidomide | 42 | suppressed |
| Pomalyst | Pomalidomide | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 17 |
| Sprycel | Dasatinib | 37 | suppressed |
| Tranexamic Acid | Tranexamic Acid | 35 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 30 | 11 |
| Furosemide | Furosemide | 29 | 13 |
| Prednisone | Prednisone | 27 | 11 |
| Olanzapine | Olanzapine | 26 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 26 | 24 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 16 |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Brukinsa | Zanubrutinib | 17 | suppressed |
| Xtandi | Enzalutamide | 17 | suppressed |
| Calquence | Acalabrutinib Maleate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Promacta | Eltrombopag Olamine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Imbruvica | Ibrutinib | 13 | suppressed |
| Ninlaro | Ixazomib Citrate | 13 | suppressed |
| Tagrisso | Osimertinib Mesylate | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,483.15 · 67 records | AstraZeneca Pharmaceuticals LP | ADCETRIS, AKEEGA, BALVERSA, BENEFIX, BLENREP, BOSULIF, BRAFTOVI, DATROWAY, ELREXFIO, ENHERTU, ENJAYMO, EPKINLY, ERLEADA, Gavreto, HYMPAVZI, IMBRUVICA, JAYPIRCA, JEMPERLI, Lenvima, MEKTOVI, NINLARO, OGSIVEO, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Optune Lua (NovoTTF-200T), Padcev, REBLOZYL, Rezlidhia, SARCLISA, TALVEY, TALZENNA, TAVALISSE, TUKYSA, Trodelvy, VENCLEXTA, VERZENIO, Vyloy, XT CDX, XTANDI, ZEJULA, ZEPZELCA | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Imbruvica play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error